302 related articles for article (PubMed ID: 21421864)
1. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.
Chang-Lin JE; Burke JA; Peng Q; Lin T; Orilla WC; Ghosn CR; Zhang KM; Kuppermann BD; Robinson MR; Whitcup SM; Welty DF
Invest Ophthalmol Vis Sci; 2011 Jun; 52(7):4605-9. PubMed ID: 21421864
[TBL] [Abstract][Full Text] [Related]
2. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.
Ahn SJ; Ahn J; Park S; Kim H; Hwang DJ; Park JH; Park JY; Chung JY; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):567-73. PubMed ID: 24398088
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.
Chang-Lin JE; Attar M; Acheampong AA; Robinson MR; Whitcup SM; Kuppermann BD; Welty D
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):80-6. PubMed ID: 20702826
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone intravitreal implant in vitrectomized versus nonvitrectomized eyes for treatment of patients with persistent diabetic macular edema.
Medeiros MD; Alkabes M; Navarro R; Garcia-Arumí J; Mateo C; Corcóstegui B
J Ocul Pharmacol Ther; 2014 Nov; 30(9):709-16. PubMed ID: 25259834
[TBL] [Abstract][Full Text] [Related]
5. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes.
Chin HS; Park TS; Moon YS; Oh JH
Retina; 2005; 25(5):556-60. PubMed ID: 16077349
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes.
Park HJ; Lee JE; Kim SI; Pak KY; Oum BS; Lee JS; Jung JH; Lee JE
Retina; 2014 Apr; 34(4):801-6. PubMed ID: 24077088
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusion.
Shaikh AH; Petersen MR; Sisk RA; Foster RE; Riemann CD; Miller DM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(1):28-33. PubMed ID: 23418731
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Efficacy and Safety of Dexamethasone Intravitreal Implants of Vitrectomized and Nonvitrectomized Eyes in a Real-World Study.
Rezkallah A; Malclès A; Dot C; Voirin N; Agard É; Vié AL; Denis P; Mathis T; Kodjikian L
J Ocul Pharmacol Ther; 2018 Oct; 34(8):596-602. PubMed ID: 30117755
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the release profile and pharmacokinetics of intact and fragmented dexamethasone intravitreal implants in rabbit eyes.
Bhagat R; Zhang J; Farooq S; Li XY
J Ocul Pharmacol Ther; 2014 Dec; 30(10):854-8. PubMed ID: 25411827
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dexamethasone implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema: A systematic review and meta-analysis.
Yuan Q; Liu Y; Gou Y; Xu H; Gao Y; Liu Y; Chen Y; Zhang M
Front Pharmacol; 2022; 13():1029584. PubMed ID: 36532786
[No Abstract] [Full Text] [Related]
12. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
13. Laser-induced intrachoroidal dexamethasone drug delivery system to posterior eye segment.
Murata M; Sanbe A; Lee JW; Nishigori H
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8317-24. PubMed ID: 24265021
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes.
Fialho SL; Rêgo MB; Siqueira RC; Jorge R; Haddad A; Rodrigues AL; Maia-Filho A; Silva-Cunha A
Curr Eye Res; 2006 Jun; 31(6):525-34. PubMed ID: 16769612
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
Boyer DS; Faber D; Gupta S; Patel SS; Tabandeh H; Li XY; Liu CC; Lou J; Whitcup SM;
Retina; 2011 May; 31(5):915-23. PubMed ID: 21487341
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.
Ahn J; Kim H; Woo SJ; Park JH; Park S; Hwang DJ; Park KH
J Ocul Pharmacol Ther; 2013 Sep; 29(7):612-8. PubMed ID: 23735192
[TBL] [Abstract][Full Text] [Related]
17. The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.
Kapoor KG; Wagner MG; Wagner AL
Semin Ophthalmol; 2015; 30(5-6):475-81. PubMed ID: 24654698
[TBL] [Abstract][Full Text] [Related]
18. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Haller JA; Bandello F; Belfort R; Blumenkranz MS; Gillies M; Heier J; Loewenstein A; Yoon YH; Jacques ML; Jiao J; Li XY; Whitcup SM;
Ophthalmology; 2010 Jun; 117(6):1134-1146.e3. PubMed ID: 20417567
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis.
Cheng CK; Berger AS; Pearson PA; Ashton P; Jaffe GJ
Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):442-53. PubMed ID: 7843913
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.
Çevik SG; Yılmaz S; Çevik MT; Akalp FD; Avcı R
J Ophthalmol; 2018; 2018():1757494. PubMed ID: 29850199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
